Transcription_NN
factors_NNS
in_IN
immune-mediated_JJ
disease_NN
._.

A_DT
large_JJ
amount_NN
of_IN
detailed_JJ
information_NN
about_IN
the_DT
intracellular_JJ
proteins_NNS
regulating_VBG
NF-kappa_NN
B_NN
activation_NN
and_CC
the_DT
cellular_JJ
response_NN
to_TO
NF-kappa_NN
B_NN
activation_NN
has_VBZ
emerged_VBN
recently_RB
._.

Several_JJ
small_JJ
molecules_NNS
,_,
an_DT
antisense_JJ
oligonucleotide_NN
,_,
and_CC
gene_NN
therapeutic_JJ
agents_NNS
that_WDT
inhibit_VBP
NF-kappa_NN
b_NN
activation_NN
have_VBP
been_VBN
described_VBN
._.

Despite_IN
this_DT
,_,
there_EX
are_VBP
still_RB
significant_JJ
gaps_NNS
in_IN
our_PRP$
understanding_NN
of_IN
this_DT
process_NN
and_CC
its_PRP$
consequences_NNS
._.

In_IN
contrast_NN
,_,
the_DT
characterization_NN
of_IN
transcription_NN
factors_NNS
selectively_RB
regulating_VBG
cytokine_NN
production_NN
by_IN
CD4_NN
+_CC
T_NN
cell_NN
subsets_NNS
is_VBZ
at_IN
a_DT
very_RB
early_JJ
stage_NN
._.

Three_CD
interacting_VBG
proteins_NNS
have_VBP
recently_RB
been_VBN
shown_VBN
to_TO
contribute_VB
to_TO
subset-restricted_JJ
expression_NN
of_IN
the_DT
IL-4_NN
gene_NN
._.

There_EX
are_VBP
other_JJ
elements_NNS
regulating_VBG
IL-4_NN
gene_NN
expression_NN
,_,
however_RB
,_,
and_CC
the_DT
relative_JJ
importance_NN
of_IN
these_DT
recently_RB
identified_VBN
proteins_NNS
has_VBZ
yet_RB
to_TO
be_VB
determined_VBN
._.

